PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant growth in short interest in May. As of May 29th, there was short interest totaling 313,070 shares, a growth of 324.9% from the May 14th total of 73,684 shares. Approximately 54.9% of the company’s stock are short sold. Based on an average daily volume of 8,718,443 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

PainReform Stock Down 8.1%

NASDAQ PRFX opened at $1.36 on Friday. PainReform has a 52 week low of $1.28 and a 52 week high of $17.95. The stock has a market capitalization of $1.18 million, a PE ratio of 0.00 and a beta of 0.98. The firm has a 50 day moving average of $1.98 and a two-hundred day moving average of $3.04.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.